Metabolic improvements from GLP-1 therapy may benefit breast cancer survivors, as obesity and insulin resistance are associated with poorer cancer outcomes
Interventions that mimic calorie restriction, clear senescent cells, or inhibit the mTOR show promise but raise concerns about safety, dosing, or feasibility
Since Ozempic came to market in 2017 to treat type 2 diabetes, drugmakers Eli Lilly and Novo Nordisk A/S have been competing to develop next-generation diabetes and weight loss drugs
ER signaling has been associated with several potential therapeutic benefits in CNS disorders: (1) it enhances GABAergic over glutamatergic signaling, exerting anticonvulsant effects (Veliskova and Desantis, 2013)
It may potentially phosphorylate various target proteins, thus initiating downstream cellular responses
Just the same as when I have tried 500mg test and 1500mg test and we learn what works for us through trial and error